This process has been attributed to the actions of a subset of cancer stem cells that possess a high degree of differentiation plasticity and can acquire a range of endothelial markers, including cluster of differentiation 31 (CD31), VEGF receptor-2 (VEGFR2), Tie2, ephrin A2, and VE-Cadherin (53, 54). This evidence concerns the gene KDR and cancer.